Abstract: Problem: to provide an activator for activating intracellular ATP production. Solution: use of a pyridodipyrimidine compound represented by the following formula (II): wherein, R1 and R3 each represent a hydrogen atom, an alkyl group, a halogen-substituted alkyl group, a carboxy-substituted alkyl group, a phenyl group, a phenyl group substituted by one of a halogen atom, a lower alkyl group, or a lower alkoxy group, or a lower alkyl disubstituted phenyl group and R2 represents an alkyl group, a cycloalkyl group, a phenyl-substituted lower alkyl group, a phenyl group, a phenyl group substituted by one of a halogen atom, a lower alkyl group, or a lower alkoxy group, or a lower alkyl disubstituted phenyl group for activating intracellular ATP production, the use comprising introducing said pyridodipyrimidine compound to a human-derived neuron cells, wherein said pyridodipyrimidine compound is used as a coenzyme factor effective for activating intracellular ATP production.

Abstract: Problem: to provide an activator for activating intracellular ATP production. Solution: use of deazaflavino-testosterone compound represented by the following formula (III): wherein, R1 represents a hydrogen atom, an alkyl group, a halogen-substituted alkyl group, a carboxy-substituted alkyl group, a phenyl group, or a phenyl group substituted by one of a halogen atom, a lower alkyl group, or a lower alkoxy group and R2 represents an alkyl group, a cycloalkyl group, a phenyl-substituted lower alkyl group, a phenyl group, a phenyl group substituted by one of a halogen atom, a lower alkyl group, or a lower alkoxy group, or a lower alkyl disubstituted phenyl group for activating intracellular ATP production, the use comprising introducing said deazaflavino-testosterone compound to a human-derived neuron cells, wherein said deazaflavino-testosterone compound is used as a coenzyme factor effective for activating intracellular ATP production.

Abstract: Problem: to provide an activator for activating intracellular ATP production. Solution: use of a 5-deazaflavin compound represented by the following formula (I): (wherein, R1 represents a hydrogen atom, an alkyl group, a halogen-substituted alkyl group, a carboxy-substituted alkyl group, or a phenyl group, R2 represents an alkyl group, a cycloalkyl group, a phenyl-substituted lower alkyl group, a phenyl group, a phenyl group substituted by one of a halogen atom, a lower alkyl group, or a lower alkoxy group, or a lower alkyl disubstituted phenyl group, and R3 and R4 each represent a hydrogen atom, a lower alkyl group, a halogen atom, a hydroxyl group, a nitro group, a cyano group, a lower alkoxy group, a phenyl-substituted lower alkoxy, a lower alkylamino group, a phenyl-substituted lower alkylamino group, or a lower alkylsulfonyl group).

Abstract: Problem: to provide an activator for activating intracellular ATP production. Solution: use of a pyridodipyrimidine compound represented by the following formula (II): wherein, R1 and R3 each represent a hydrogen atom, an alkyl group, a halogen-substituted alkyl group, a carboxy-substituted alkyl group, a phenyl group, a phenyl group substituted by one of a halogen atom, a lower alkyl group, or a lower alkoxy group, or a lower alkyl disubstituted phenyl group and R2 represents an alkyl group, a cycloalkyl group, a phenyl-substituted lower alkyl group, a phenyl group, a phenyl group substituted by one of a halogen atom, a lower alkyl group, or a lower alkoxy group, or a lower alkyl disubstituted phenyl group for activating intracellular ATP production, the use comprising introducing said pyridodipyrimidine compound to a human-derived neuron cells, wherein said pyridodipyrimidine compound is used as a coenzyme factor effective for activating intracellular ATP production.

Abstract: Problem: to provide an activator for activating intracellular ATP production. Solution: use of deazaflavino-testosterone compound represented by the following formula (III): wherein, R1 represents a hydrogen atom, an alkyl group, a halogen-substituted alkyl group, a carboxy-substituted alkyl group, a phenyl group, or a phenyl group substituted by one of a halogen atom, a lower alkyl group, or a lower alkoxy group and R2 represents an alkyl group, a cycloalkyl group, a phenyl-substituted lower alkyl group, a phenyl group, a phenyl group substituted by one of a halogen atom, a lower alkyl group, or a lower alkoxy group, or a lower alkyl disubstituted phenyl group for activating intracellular ATP production, the use comprising introducing said deazaflavino-testosterone compound to a human-derived neuron cells, wherein said deazaflavino-testosterone compound is used as a coenzyme factor effective for activating intracellular ATP production.

Abstract: The present invention provides novel triazolopyrimidines derived from nucleobase thymine, and methods of producing the same, as well as various biologically active substances obtained by the methods, particularly antitumor agents. The triazolopyrimidine compounds represented by the following formulas (I) to (VIII) (wherein R represents a hydrogen atom, an alkyl group, or an aryl group) and methods of producing the same.

Abstract: The present invention relates to a hydrazinopurine compound or triazolopurine compound represented by the general formula (wherein R1, R3, R4, R6, R8, R10, and R12 represent hydrogen atom or alkyl group; and R2, R5, R7, R9, R11, and R13 represent hydrogen atom, alkyl group, or an aryl group), a xanthine oxidase inhibitory composition containing the abovementioned compound as an active ingredient, and a medicinal composition containing the abovementioned compound as an active ingredient, particularly a medicinal composition for preventing or treating hyperuricemia, gout, and a disease caused by hyperuricemia.

Abstract: Problem: to provide an activator for activating intracellular ATP production. Solution: use of a 5-deazaflavin compound represented by the following formula (I): (wherein, R1 represents a hydrogen atom, an alkyl group, a halogen-substituted alkyl group, a carboxy-substituted alkyl group, or a phenyl group, R2 represents an alkyl group, a cycloalkyl group, a phenyl-substituted lower alkyl group, a phenyl group, a phenyl group substituted by one of a halogen atom, a lower alkyl group, or a lower alkoxy group, or a lower alkyl disubstituted phenyl group, and R3 and R4 each represent a hydrogen atom, a lower alkyl group, a halogen atom, a hydroxyl group, a nitro group, a cyano group, a lower alkoxy group, a phenyl-substituted lower alkoxy, a lower alkylamino group, a phenyl-substituted lower alkylamino group, or a lower alkylsulfonyl group).

Abstract: Purine or triazolopurine compounds are disclosed represented by formula (I) or (II): ##STR1## wherein R.sup.1 and R.sup.4 represent each hydrogen, halogeno, hydroxy, mercapto, or amino; R.sup.2 represents alkyl or aryl; and R.sup.3 and R.sup.5 represent each hydrogen, alkyl, or aryl; and pharmaceutical compositions comprising these compounds as xanthine oxidase inhibitors, remedies for hyperuricemia, or remedies or preventive agents for gout.